UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000050580
Receipt number R000057139
Scientific Title Randomized controlled trial for implementation of ALDH2 genotyping in the healthcare system
Date of disclosure of the study information 2023/04/01
Last modified on 2023/03/14 14:05:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of ALDH2 genotyping for health promotion

Acronym

AGHP

Scientific Title

Randomized controlled trial for implementation of ALDH2 genotyping in the healthcare system

Scientific Title:Acronym

AGHP

Region

Japan


Condition

Condition

Undesirable lifestyle habits

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To test whether notification of the rs671 polymorphism of the aldehyde dehydrogenase gene (ALDH2) can promote behavioral changes in lifestyle habits. This will demonstrate the usefulness of ALDH2 rs671 polymorphism determination and provide evidence for dissemination and implementation of the testing.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Frequency of drinking, amount of drinking, frequency of heavy drinking, stages of behavioral modification, perceptions of drinking habits, and stress coping

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Other

Interventions/Control_1

Notification of ALDH2 gene rs671 polymorphism and sharing of health information related to rs671

Interventions/Control_2

Notification of ALDH2 gene rs671 polymorphism and sharing of health information related to rs671
Acetaldehyde exposure marker testing and objective sleep assessment

Interventions/Control_3

Notification of ALDH2 gene rs671 polymorphism and sharing of health information related to rs671 at the end of the observation period

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

Employees of workplaces in Saga Prefecture.

Key exclusion criteria

(1) Those who are not receiving treatment for a serious physical or mental illness
(2) Those who are receiving sleep treatment for depression or mental illness.
(3) Those who are unable to participate in the entire survey due to their existing commitments.
(4) Other subjects deemed inappropriate by the industrial physician at their workplace.
(5) Those who have requested discontinuation of the study (those who have submitted a consent withdrawal form).

Target sample size

650


Research contact person

Name of lead principal investigator

1st name Akiko
Middle name
Last name Matsumoto

Organization

Saga University

Division name

School of Medicine

Zip code

849-8501

Address

5-1-1 Nabeshima

TEL

0952342289

Email

matsumoa@cc.saga-u.ac.jp


Public contact

Name of contact person

1st name Mikiko
Middle name
Last name Tokiya

Organization

Saga University

Division name

School of Medicine

Zip code

849-8501

Address

5-1-1 Nabeshima, Saga

TEL

0952342289

Homepage URL

https://sagasocialmed.med.saga-u.ac.jp/research/aldh%EF%BC%92%E3%81%AE%E5%9E%8B%E3%81%AB%E5%BF%9C%E3

Email

matsumoa@cc.saga-u.ac.jp


Sponsor or person

Institute

Saga University

Institute

Department

Personal name

Akiko Matsumoto


Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Saga University

Address

5-1-1 Nabeshima Saga

Tel

0952-31-6511

Email

matsumoa@cc.saga-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 12 Month 01 Day

Date of IRB

2022 Year 12 Month 01 Day

Anticipated trial start date

2022 Year 12 Month 01 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 03 Month 14 Day

Last modified on

2023 Year 03 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057139


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name